Chronus develops in-vitro point-of-care devices leveraging microfluidics and semiconductor technologies.

RealTime provides software for clinical trial research sites, site networks, sponsors and CROs to manage complex clinical research processes

Akura Medical is developing a next generation thrombectomy device to remove blood clots.

Renovo is one of the only national providers focused exclusively on managing health care and life sciences equipment and technology,

BIOiSIM is a first-in-class 'virtual drug development engine' that offers unprecedented value for the drug development industry.

Avenge Bio is developing transformative cell-based immunotherapeutic products for the treatment of intractable solid tumors.

Caira's proprietary technology seeks to revolutionize the usability, safety, and accessibility of advanced surgical navigation and robotics.

Amberstone’s T-MATE therapeutic molecules enabled by its innovative single-cell discovery engine represents a real breakthrough.

Curi Bio’s technology platforms create value for pharma and biotech companies by accelerating discovery timelines and increasing success.

DiRx is an online pharmacy that delivers savings on commonly prescribed, FDA-approved generic medicines without the need for insurance.

Curi Bio’s technology platforms create significant value for pharma and biotech companies by accelerating discovery timelines.

Helix is the leading population genomics company operating at the intersection of clinical care, research, and genomics.

Unlike tank-based systems, GENOSYL DS generates NO at the bedside using a small disposable cassette.

The company's FlowSense™ noninvasive wireless sensor addresses a clinical unmet need for patients with hydrocephalus.

Oncorena's Phase I/II clinical trial of orellanine will enrol patients with advanced renal cancer already on dialysis due to renal failure.

The use of funds will include clinical program expansion and commercialization of the CAPTIS full-body embolic protection system.

Apella’s products include sensors installed in the operating room and harness artificial intelligence approaches to collect and analyze data

The financing provides capital to complete the clinical trial for the Ventura Interatrial Shunt for the treatment of advanced heart failure.

Soarta Biomedical's Biomimetic Implant is a minimally invasive treatment for chondral or osteochondral defects of the knee cartilage.

In 2020, the Lithuanian biotech sector showed annual growth of 87% producing enormous profit for stakeholders.

"Our team has a groundbreaking approach to early detection of cancer."

Corganics' clinical cannabinoid therapy portfolio is available exclusively through healthcare professionals.

"Our mission is to improve human health by providing scientists with the tools they need to measure proteins at high resolution...

NanoMosaic is leveraging the power of nanoneedles, MosaicNeedle, for protein detection and quantification to develop alloys for biomarkers.

Curexa’s broad range of services include pre-launch support, customized formulations, API integration, and packaging/branding

Avivomed is developing and commercializing next generation neuromodulaton technology to treat patients suffering from chronic diseases.

MANA Therapeutics is harnessing the natural immune system to develop broadly accessible, ready-to-use cellular therapies to improve outcomes

Lunit develops AI-powered diagnostic tools for cancer screening, and biomarkers that can predict patients who respond to specific therapies.

The company's lead product utilizes a novel, non-invasive drug-device combination for outpatient treatment of rGBM.

HealthSnap helps healthcare providers manage chronic conditions such as hypertension, diabetes, and heart failure.

Parthenon Therapeutics is inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment (TME).

In the past year, Infusion for Health has more than quadrupled the size of its business and geographic reach to more than 20 million lives.

Exosystems is known for its digital care solution which consists of a wearable medical device and connected user app.

The FDA has granted Magnus Breakthrough Device Designation for its individualized, rapid-acting, non-invasive neurostimulation technology.

Cardiogram's cardiovascular health decision support application helps users manage chronic health conditions.

DeepSight Technology provides a platform to enhance non-invasive and invasive medical imaging for multiple diagnostic procedures.

Sai Life Sciences is a CRO-CDMO that enables pharma and biotech companies to accelerate the discovery and development of small molecules.

Octave Bioscience was founded to deliver an end-to-end care management platform for multiple sclerosis and neurodegenertive diseases.

Our NanoGalaxy platform of non-viral, non-lipid polymer nanoparticles will enable opportunities to launch genetic medicines.

"We see the potential to treat many neuromuscular diseases with a single gene therapy."

Tuune intends to improve the healthcare experience for women, starting with more informed birth control choices.

Most of the new treatments for fighting cancer, rare diseases, and infections are made possible because of advances in viral medicines.

The processing and storage of blood for transfusion is fundamental to healthcare, and over 90 million units of are transfused annually.

The proceeds of a net half million euro from the round will advance the development of company’s lead product candidate.

The funding will accelerate the commercialization of Kytopen’s high-throughput automated platform which links discovery to manufacturing.

Envisagenics' R&D focuses on diseases that are caused in part by RNA splicing deregulation and have patient populations with unmet needs.

Garuda is developing an off-the-shelf hematopoietic stem cell platform that will eliminate dependency on donor or patient cells.

Elevian's novel approach could be transformational and bring hope to the millions of stroke victims around the world every year.

Our goal is to become the preferred therapeutic system for patients with reduced tissue perfusion, such as those with PAD and CLI.

Alebund Pha has built a diversified pipeline of drug candidates after three years of rapid growth, targeting a range of major renal diseases